Nuveen Asset Management LLC Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Nuveen Asset Management LLC boosted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 0.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 944,601 shares of the biopharmaceutical company's stock after purchasing an additional 8,802 shares during the period. Nuveen Asset Management LLC owned about 0.16% of Royalty Pharma worth $24,097,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of RPRX. Occudo Quantitative Strategies LP boosted its stake in shares of Royalty Pharma by 96.4% in the 4th quarter. Occudo Quantitative Strategies LP now owns 22,512 shares of the biopharmaceutical company's stock valued at $574,000 after purchasing an additional 11,052 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Royalty Pharma by 25.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 66,501 shares of the biopharmaceutical company's stock valued at $1,696,000 after purchasing an additional 13,376 shares in the last quarter. Ethic Inc. increased its stake in shares of Royalty Pharma by 132.6% in the fourth quarter. Ethic Inc. now owns 20,342 shares of the biopharmaceutical company's stock valued at $519,000 after buying an additional 11,597 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in Royalty Pharma by 24.6% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,161,304 shares of the biopharmaceutical company's stock valued at $29,625,000 after buying an additional 228,964 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in Royalty Pharma by 36.2% during the 4th quarter. Deutsche Bank AG now owns 3,189,964 shares of the biopharmaceutical company's stock worth $81,376,000 after acquiring an additional 847,704 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Stock Up 0.2%

NASDAQ:RPRX traded up $0.06 during trading hours on Wednesday, reaching $32.75. The company had a trading volume of 329,893 shares, compared to its average volume of 3,461,539. The firm has a market cap of $18.88 billion, a price-to-earnings ratio of 22.59, a P/E/G ratio of 2.31 and a beta of 0.49. The business's 50-day simple moving average is $32.36 and its two-hundred day simple moving average is $30.28. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.32.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The company had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. On average, equities analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.69%. Royalty Pharma's payout ratio is 47.57%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on RPRX shares. Citigroup restated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Wall Street Zen cut shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, May 20th. Finally, Morgan Stanley initiated coverage on Royalty Pharma in a report on Friday, May 16th. They set an "overweight" rating and a $51.00 price target for the company. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.